RHJA
ACRS icon

Rice Hall James & Associates’s Aclaris Therapeutics ACRS Stock Holding History

Rice Hall James & Associates’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-511,579
Closed -$1.12M – 270
2019
Q2 		$1.12M Sell
511,579
-187,728
-27% -$1.02M 0.04% 235
2019
Q1 		$4.19M Buy
699,307
+158,056
+29% +$1.05M 0.13% 133
2018
Q4 		$4M Buy
541,251
+151,254
+39% +$1.56M 0.15% 128
2018
Q3 		$5.66M Sell
389,997
-9,345
-2% -$160K 0.2% 114
2018
Q2 		$7.97M Buy
399,342
+187,545
+89% +$3.47M 0.29% 109
2018
Q1 		$3.71M Buy
211,797
+145,988
+222% +$3.09M 0.14% 119
2017
Q4 		$1.62M Buy
65,809
+24,325
+59% +$592K 0.06% 230
2017
Q3 		$1.07M Sell
41,484
-1,385
-3% -$37.1K 0.05% 234
2017
Q2 		$1.16M Buy
42,869
+8,042
+23% +$219K 0.05% 235
2017
Q1 		$1.04M Buy
34,827
+93
+0.3% +$2.68K 0.05% 246
2016
Q4 		$943K Buy
+34,734
New +$886K 0.05% 248

Other funds holding ACRS

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rice Hall James & Associates's ACRS Position: Q3 2019 in Review

Rice Hall James & Associates sold out of Aclaris Therapeutics (ACRS) in Q3 2019, closing a stake of 511,579 shares — an estimated $1.12M sold.

Rice Hall James & Associates first reported a position in ACRS in Q4 2016 and held it in 11 quarters. The position peaked at $7.97M in Q2 2018. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2019.

  • Rice Hall James & Associates reported no remaining Aclaris Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 511,579 Aclaris Therapeutics shares in Q3 2019, an estimated $1.12M.
  • Rice Hall James & Associates first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 11 quarters.
  • Rice Hall James & Associates's Aclaris Therapeutics position peaked at $7.97M in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2019.

Based on Rice Hall James & Associates's 13F filing for Q3 2019, filed 30 Oct 2019.